Your browser doesn't support javascript.
loading
Association of antibiotics with the outcomes in COVID-19 pneumonia patients with elevated PCT levels.
Raavi, Lekhya; Isha, Shahin; Jonna, Sadhana; Craver, Emily C; Nataraja, Hrishikesh; Jenkins, Anna; Hanson, Abby J; Venkataraman, Arvind Bala; Balasubramanian, Prasanth; Tekin, Aysun; Bansal, Vikas; Caples, Sean M; Khan, Syed Anjum; Jain, Nitesh K; LaNou, Abigail T; Kashyap, Rahul; Cartin-Ceba, Rodrigo; Patel, Bhavesh M; Milian, Ricardo Diaz; Venegas, Carla P; Shapiro, Anna B; Bhattacharyya, Anirban; Chaudhary, Sanjay; Kiley, Sean P; Erben, Young M; Quinones, Quintin J; Patel, Neal M; Guru, Pramod K; Franco, Pablo Moreno; Roy, Archana; Sanghavi, Devang K.
Afiliação
  • Raavi L; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Isha S; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Jonna S; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Craver EC; Department of Quantitative Health Sciences, Mayo Clinic in Florida, USA.
  • Nataraja H; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Jenkins A; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Hanson AJ; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Venkataraman AB; Department of Pulmonary and Critical Care, Mayo Clinic in Florida, USA.
  • Balasubramanian P; Department of Pulmonary and Critical Care, Mayo Clinic in Florida, USA.
  • Tekin A; Department of Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Bansal V; Department of Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Caples SM; Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, Minnesota, USA.
  • Khan SA; Department of Critical Care Medicine, Mayo Clinic Health System in Mankato, USA.
  • Jain NK; Department of Critical Care Medicine, Mayo Clinic Health System in Mankato, USA.
  • LaNou AT; Emergency Medicine and Critical Care, Mayo Clinic Health System, Eau Claire, WI, USA.
  • Kashyap R; Department of Anesthesia and Critical Care Medicine, Mayo Clinic Rochester, Minnesota, USA.
  • Cartin-Ceba R; Department of Critical Care Medicine, Mayo Clinic, Arizona, USA.
  • Patel BM; Department of Critical Care Medicine, Mayo Clinic, Arizona, USA.
  • Milian RD; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Venegas CP; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Shapiro AB; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Bhattacharyya A; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Chaudhary S; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Kiley SP; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Erben YM; Division of Vascular and Endovascular Surgery, Mayo Clinic, Jacksonville, FL, USA.
  • Quinones QJ; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Patel NM; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Guru PK; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Franco PM; Department of Critical Care Medicine, Mayo Clinic in Florida, USA.
  • Roy A; Division of Hospital Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
  • Sanghavi DK; Department of Critical Care Medicine, Mayo Clinic in Florida, USA. Electronic address: sanghavi.devang@mayo.edu.
Respir Med ; 231: 107697, 2024 09.
Article em En | MEDLINE | ID: mdl-38857810
ABSTRACT

OBJECTIVE:

To assess antibiotics impact on outcomes in COVID-19 pneumonia patients with varying procalcitonin (PCT) levels.

METHODS:

This retrospective cohort study included 3665 COVID-19 pneumonia patients hospitalized at five Mayo Clinic sites (March 2020 to June 2022). PCT levels were measured at admission. Patients' antibiotics use and outcomes were collected via the Society of Critical Care Medicine (SCCM) Viral Infection and Respiratory Illness Universal Study (VIRUS) registry. Patients were stratified into high and low PCT groups based on the first available PCT result. The distinction between high and low PCT was demarcated at both 0.25 ng/ml and 0.50 ng/ml.

RESULTS:

Our cohort consisted of 3665 patients admitted with COVID-19 pneumonia. The population was predominantly male, Caucasian and non-Hispanic. With the PCT cut-off of 0.25 ng/ml, 2375 (64.8 %) patients had a PCT level <0.25 ng/mL, and 1290 (35.2 %) had PCT ≥0.25 ng/ml. While when the PCT cut off of 0.50 ng/ml was used we observed 2934 (80.05 %) patients with a PCT <0.50 ng/ml while 731(19.94 %) patients had a PCT ≥0.50 ng/ml. Patients with higher PCT levels exhibited significantly higher rates of bacterial infections (0.25 ng/ml cut-off 4.2 % vs 7.9 %; 0.50 ng/ml cut-off 4.6 % vs 9.2 %). Antibiotics were used in 66.0 % of the cohort. Regardless of the PCT cutoffs, the antibiotics group showed increased hospital length of stay (LOS), intensive care unit (ICU) admission rate, and mortality. However, early de-escalation (<24 h) of antibiotics correlated with reduced hospital LOS, ICU LOS, and mortality. These results were consistent even after adjusting for confounders.

CONCLUSION:

Our study shows a substantial number of COVID-19 pneumonia patients received antibiotics despite a low incidence of bacterial infections. Therefore, antibiotics use in COVID pneumonia patients with PCT <0.5 in the absence of clinical evidence of bacterial infection has no beneficial effect.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Calcitonina / COVID-19 / Antibacterianos Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Calcitonina / COVID-19 / Antibacterianos Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article